Remove 2022 Remove BioTech Remove Digital Health Remove Drug Development
article thumbnail

Let’s Save the Date and Make Patient Engagement Official in 2022

Society for Participatory Medicine

Healthcare stakeholders such as health systems, pharmaceutical companies, biotech and life sciences firms, and insurance companies serve patients as end users. Market forces drove acceleration in digital health, specifically telemedicine, which were sorely needed for several years. Connect with her at [link].

BioTech 107
article thumbnail

QuantHealth Announces $15M Series A for its AI Platform That Enhances Success of Clinical Trials

Digital Health Global

QuantHealth bridges these gaps by simulating trials at scale, to expedite, derisk, and optimize drug development. QuantHealth proudly supports several large pharma companies, numerous biotechs, as well as CROs, and other industry partners.

BioTech 88
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

AstraZeneca launches Evinova, a health-tech business to accelerate innovation across the life sciences sector, the delivery of clinical trials and better health outcomes

Digital Health Global

–(BUSINESS WIRE)–AstraZeneca today launches Evinova, set to be a leading provider of digital health solutions to better meet the needs of healthcare professionals, regulators and patients.

article thumbnail

Turbine Upsizes its Series A Round to €25.5 Million and Appoints Seasoned Independent Directors to its Board

Digital Health Global

These individuals have personally built leading technology platforms supercharging drug development globally. Their buy-in shows that our platform is differentiated and poised to unlock truly novel therapies for currently underserved patient populations through efficient, simulation-guided development. Jane Rhodes, Ph.D.,

BioTech 88
article thumbnail

Accelerator Life Science Partners Launches Biotechnology Startup Company in Singapore with $16M in Series A Commitments

Digital Health Global

About Automera Automera is an early-stage company focused on the development of a novel therapeutic approach via autophagy-based targeted protein degradation. ClavystBio was conceived and launched by Temasek to be a venture builder, trusted partner, and keystone to catalyze global health solutions from Singapore.